D. E. Shaw & Co., Inc. - TRAVERE THERAPEUTICS INC ownership

TRAVERE THERAPEUTICS INC's ticker is and the CUSIP is 89422GAA5. A total of 26 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.5%.

Quarter-by-quarter ownership
D. E. Shaw & Co., Inc. ownership history of TRAVERE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$26,279,495
-20.4%
40,689,0000.0%0.03%
-20.6%
Q2 2023$33,015,536
-12.0%
40,689,000
+6.5%
0.03%
-15.0%
Q1 2023$37,523,700
+8.0%
38,189,0000.0%0.04%
+5.3%
Q4 2022$34,756,223
+17.5%
38,189,000
+31.7%
0.04%
+8.6%
Q3 2022$29,571,000
+1.6%
29,000,0000.0%0.04%
+2.9%
Q2 2022$29,118,000
-2.5%
29,000,000
+3.6%
0.03%
+21.4%
Q1 2022$29,869,00028,000,0000.03%
Other shareholders
TRAVERE THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
Perceptive Advisors 45,000,000$474,089,0009.50%
ABSOLUTE INVESTMENT ADVISERS, LLC 4,000,000$4,280,0000.96%
DeepCurrents Investment Group LLC 22,150,000$23,650,0000.74%
HIGHBRIDGE CAPITAL MANAGEMENT LLC 19,000,000$19,967,0000.46%
Context Capital Management, LLC 5,750$6,138,0000.40%
WOLVERINE ASSET MANAGEMENT LLC 34,000,000$36,271,0000.35%
Polar Asset Management Partners Inc. 15,000,000$15,993,0000.17%
LINDEN ADVISORS LP 20,000,000$21,281,0000.13%
Wellesley Asset Management 1,599$1,599,0000.11%
Verition Fund Management LLC 6,213,000$6,614,0000.08%
View complete list of TRAVERE THERAPEUTICS INC shareholders